25 Participants Needed

Cryoneurolysis for Spasticity

SP
FM
Overseen ByFraser MacRae, BSc
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

Yes, you will need to stop taking any antispastic medications during the follow-up period of the trial.

What data supports the effectiveness of the treatment Cryoneurolysis for spasticity?

Research shows that cryoneurolysis, a treatment that involves freezing nerves to reduce pain and muscle tightness, can improve movement and function in patients with spasticity. For example, a case study reported improved shoulder movement and daily activities in a child with cerebral palsy after the treatment. Additionally, cryotherapy, a similar cold treatment, has been shown to temporarily reduce spasticity in patients with brain and spinal cord injuries.12345

How does the treatment Cryoneurolysis differ from other treatments for spasticity?

Cryoneurolysis is unique because it involves freezing specific nerves to reduce spasticity, which is different from other treatments that may use medications or physical therapy to manage symptoms. This method targets the nerves directly, potentially offering a more localized and immediate effect.678910

What is the purpose of this trial?

Spasticity can make regular daily activities difficult or impossible. Cryoneurolysis is a new technique to treat spasticity that is currently being tested. For this technique, a needle is inserted alongside a nerve implicated in spasticity. The needle then freezes and causes the nerve to break down. The nerve breaking down seems to provide relief for spasticity. The investigators are interested in testing the long-term effects of cryoneurolysis on the function of the brain over six months after treatment. The investigators are testing the brain's function using transcranial magnetic stimulation (TMS) which involves a magnet activating specific parts of the brain that cause muscles to fire; magnetic resonance imaging (MRI) which uses to examine brain structure; functional near-infrared spectroscopy (fNIRS) to examine brain function. The investigators believe that there will be a change in these measures that are related to the long-lasting effects of cryoneurolysis. Cryoneurolysis is not a part of standard care after stroke but is approved in Canada for patients. It has been used extensively in the past for treating pain. TMS is a way of studying how the brain sends signals to muscles to make movement. During these sessions, a researcher will use a magnet to turn on specific neurons in the brain that will cause muscles to contract. The investigators can study the way eyes and muscles respond to better understand how the brain is sending information about moving the body to the muscles. FNIRS is a new way of studying how the brain works. During these sessions, a researcher will fit the participant with a cap that has several lights on it. The light travels through hair, scalp, and skull where it interacts with blood in the brain. By studying the changes in the colour of the blood in the brain, researchers can understand which parts of the brain are active during specific tasks. Magnetic Resonance Imaging (MRI) involves a powerful magnet that takes very detailed pictures of the brain. These images help the investigators to understand how a stroke is related to spasticity. Also, these images are helpful to make the stimulation with TMS more accurate. Study participation will require five visits to the Parkwood Institute Main Building and one visit to St. Joseph's Hospital. The entire study will take place over roughly six months. The investigators are recruiting 25 people with stroke who are eligible for cryoneurolysis to participate in the study.

Research Team

SP

Sue Peters, PhD

Principal Investigator

Western University

Eligibility Criteria

This trial is for individuals with spasticity, a condition that can interfere with daily activities. Participants should have had a stroke and be eligible for cryoneurolysis treatment in Canada. The study involves six visits over six months to specific hospitals.

Inclusion Criteria

Can understand and follow instructions in English
I can slightly move my arms or hands.
Patient at Parkwood Institute
See 4 more

Exclusion Criteria

Have contraindications to TMS (i.e., history of seizure, pregnancy) or 3T MRI (i.e., certain metallic implants)
I am able to understand and agree to the study's requirements.
I am taking medication for muscle spasms during the study.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Participants receive cryoneurolysis treatment, involving the application of extreme cold to targeted nerves under ultrasound guidance

1 day
1 visit (in-person)

Follow-up

Participants are monitored for changes in spasticity severity and brain function using TMS, MRI, and fNIRS

6 months
5 visits (in-person) at Parkwood Institute, 1 visit (in-person) at St. Joseph's Hospital

Long-term Monitoring

Participants' health-related quality of life, range of motion, and grip strength are assessed over time

6 months

Treatment Details

Interventions

  • Cryoneurolysis
Trial Overview The trial tests the long-term effects of cryoneurolysis on brain function in people with spasticity. It uses techniques like transcranial magnetic stimulation (TMS), MRI, and functional near-infrared spectroscopy (fNIRS) to assess changes in the central nervous system.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Each participant will receive cryoneurolysis which involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance. This cold causes axonotmesis to occur, thereby completely preventing the treated nerve from propagating any signal. Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact. Therefore, the axon can regenerate, following the same path as prior to treatment.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sue Peters

Lead Sponsor

Pacira Pharmaceuticals, Inc

Industry Sponsor

Trials
142
Recruited
14,300+
Headquarters
Tampa, USA
Known For
Non-opioid Pain Management
Top Products
Exparel, Zilretta, iovera
Dr. Jonathan Slonin profile image

Dr. Jonathan Slonin

Pacira Pharmaceuticals, Inc

Chief Medical Officer since 2020

BSc in Biomedical Engineering and MD from University of Miami, MBA from George Washington University

Frank D. Lee

Pacira Pharmaceuticals, Inc

Chief Executive Officer since 2024

BSc in Chemical Engineering from Vanderbilt University, MBA from Wharton Graduate School of Business

Findings from Research

In a study involving 113 patients undergoing ultrasound-guided percutaneous cryoneurolysis for spasticity, 96.75% of nerve treatments resulted in no significant pain or dysesthesias beyond the treatment period, indicating a high safety profile.
While a few patients experienced temporary nerve pain or numbness, most adverse effects were manageable and resolved within three months, suggesting that cryoneurolysis could be a safe and effective treatment option for spasticity.
Analysis of Adverse Effects of Cryoneurolysis for the Treatment of Spasticity.Winston, P., MacRae, F., Rajapakshe, S., et al.[2023]

References

Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use. [2022]
Analysis of Adverse Effects of Cryoneurolysis for the Treatment of Spasticity. [2023]
Case Report: Perspective of a Caregiver on Functional Outcomes Following Bilateral Lateral Pectoral Nerve Cryoneurotomy to Treat Spasticity in a Pediatric Patient With Cerebral Palsy. [2022]
[Evaluation of effectiveness of local cryotherapy in patients with post-stroke spasticity]. [2016]
Influence of cryotherapy on spasticity at the human ankle. [2006]
Patients with n-hexane induced polyneuropathy: a clinical follow up. [2019]
N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) suppresses neuritic degeneration caused by different experimental paradigms including in vitro Wallerian degeneration. [2014]
Intra-arterial injection of diisopropylfluorophosphate or phenylmethanesulphonyl fluoride produces unilateral neuropathy or protection, respectively, in hens. [2019]
Delayed myelopathy after organophosphate intoxication: A case report. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Peripheral nerve damage in chicks following treatment with organophosphorus compounds in ovo. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security